- Investing.com
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson’s disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer’s disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.
Metrics to compare | VAXX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVAXXPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −3.0x | −0.6x | |
PEG Ratio | 0.00 | −0.04 | 0.00 | |
Price/Book | 0.0x | 1.8x | 2.6x | |
Price / LTM Sales | - | 28.0x | 3.2x | |
Upside (Analyst Target) | - | 190.1% | 46.2% | |
Fair Value Upside | Unlock | 13.2% | 7.0% | Unlock |